SynthesisFrontiers in physiology2022
Deep learning techniques for cancer classification using microarray gene expression data.
Synthesis in Frontiers in physiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Near-infrared/glutathione-activated CRISPR/Cas13a sensing platform for the detection of multiple microRNAs.RSC advances · 2026Article
- Article
- Bioinformatics strategies and biomarker refinement using high-throughput transcriptome data in transplantation.Frontiers in bioinformatics · 2026Article
- Trends in artificial intelligence and machine learning for renal cancer.Discover oncology · 2025Article
- Integrative bioinformatics and machine learning approaches identify inflammation-related genes and drug candidates for future preclinical validation in ischemic stroke.BMC neurology · 2025Article
- Building simplified cancer subtyping and prediction models with glycan gene signatures.Cell reports methods · 2025Article
- Integrated Meta-Analysis Identifies Keratin Family Genes and Associated Genes as Key Biomarkers and Therapeutic Targets in Metastatic Cutaneous Melanoma.Diagnostics (Basel, Switzerland) · 2025Article
- Semi-supervised data-integrated feature importance enhances performance and interpretability of biological classification tasks.Bioinformatics (Oxford, England) · 2025Article
- Enhanced Superpixel-Guided ResNet Framework with Optimized Deep-Weighted Averaging-Based Feature Fusion for Lung Cancer Detection in Histopathological Images.Diagnostics (Basel, Switzerland) · 2025Article
- Bridging the gap: The role of technological advances in shaping gastrointestinal oncological outcomes.World journal of gastrointestinal oncology · 2025Article
- Development of a Mitochondrial Membrane Permeability Transition Prognosis System in Colon Adenocarcinoma: Risk Stratification and Therapeutic Target Identification.Current medicinal chemistry · 2025Article
- Feature Selection for Hypertension Risk Prediction Using XGBoost on Single Nucleotide Polymorphism Data.Healthcare informatics research · 2025Article
- Optimal features selection in the high dimensional data based on robust technique: Application to different health database.Heliyon · 2024Review
- Article
- Improving prediction of blood cancer using leukemia microarray gene data and Chi2 features with weighted convolutional neural network.Scientific reports · 2024Article
- Glycosaminoglycan microarrays for studying glycosaminoglycan-protein systems.Carbohydrate polymers · 2024Review
- Unravelling the diagnostic pathology and molecular biomarkers in lung cancer.Breathe (Sheffield, England) · 2024Review
- Enhancement of Classifier Performance with Adam and RanAdam Hyper-Parameter Tuning for Lung Cancer Detection from Microarray Data-In Pursuit of Precision.Bioengineering (Basel, Switzerland) · 2024Article
- Emerging Multifunctional Carbon-Nanomaterial-Based Biosensors for Cancer Diagnosis.Small science · 2024Article
- Cancer genetics and deep learning applications for diagnosis, prognosis, and categorization.Journal of biological methods · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is one of the top causes of death globally. Recently, microarray gene expression data has been used to aid in cancer's effective and early detection. The use of DNA microarray technology to uncover information from the expression levels of thousands of genes has enormous promise. The DNA microarray technique can determine the levels of thousands of genes simultaneously in a single experiment. The analysis of gene expression is critical in many disciplines of biological study to obtain the necessary information. This study analyses all the research studies focused on optimizing gene selection for cancer detection using artificial intelligence. One of the most challenging issues is figuring out how to extract meaningful information from massive databases. Deep Learning architectures have performed efficiently in numerous sectors and are used to diagnose many other chronic diseases and to assist physicians in making medical decisions. In this study, we have evaluated the results of different optimizers on a RNA sequence dataset. The Deep learning algorithm proposed in the study classifies five different forms of cancer, including kidney renal clear cell carcinoma (KIRC), Breast Invasive Carcinoma (BRCA), lung adenocarcinoma (LUAD), Prostate Adenocarcinoma (PRAD) and Colon Adenocarcinoma (COAD). The performance of different optimizers like Stochastic gradient descent (SGD), Root Mean Squared Propagation (RMSProp), Adaptive Gradient Optimizer (AdaGrad), and Adaptive Momentum (AdaM). The experimental results gathered on the dataset affirm that AdaGrad and Adam. Also, the performance analysis has been done using different learning rates and decay rates. This study discusses current advancements in deep learning-based gene expression data analysis using optimized feature selection methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.